Poolbeg Pharma plc – POLB 001 patent granted in South Africa for the treatment or prevention of hypercytokinemia and severe influenza

/in

Patent decision strengthens Poolbeg’s intellectual property portfolio 30 June 2026 – Poolbeg Pharma (AIM: POLB, ‘Poolbeg’ or the ‘Company’), a clinical-stage biopharmaceutical company with a core focus on transforming the cancer immunotherapy field, announces it has received notification of the official decision to grant Poolbeg’s Immunomodulator II patent in South Africa, providing protection for POLB 001 for the prevention of hypercytokinaemia and […]

Read more

Hansa Biopharma announces ConfIdeS Phase 3 Abstract Selected for ‘What’s Hot, What’s New’ Plenary at ATC 2026

/in

Lund, Sweden, June 24, 2026. Hansa Biopharma AB, “Hansa” (Nasdaq Stockholm: HNSA), today announced that the ConfIdeS Phase 3 abstract titled “Superior 1-year eGFR Among Highly Sensitized Patients Desensitized with Imlifidase Compared to Control” has been selected to be highlighted at the closing plenary session “What’s Hot, What’s New” at the American Transplant Congress (ATC) 2026, […]

Read more

Novo Nordisk Foundation: New European initiative to accelerate drug discovery for cardiometabolic diseases

/in

The Novo Nordisk Foundation is funding a new pan-European initiative to accelerate drug discovery and the development of next generation therapeutics for cardiometabolic diseases (CMDs). The initiative addresses one of today’s most pressing global challenges: Translating promising research into improved care for people living with CMDs. Despite Europe’s strong position in CMD research, many promising […]

Read more

Kither Biotech successfully completes Phase 1 clinical trial of KIT2014, a novel inhaled peptide therapy for respiratory diseases

/in

First-in-human Phase 1 study in 56 healthy participants demonstrated KIT2014’s safety and tolerability KIT2014 is being developed as an inhalation therapy for respiratory diseases including chronic obstructive pulmonary disease (COPD), non-CF bronchiectasis (NCFB) and cystic fibrosis (CF) KIT2014’s unique mode of action improves respiratory symptoms by promoting bronchodilation and reducing lung inflammation   Turin, Italy […]

Read more

BIO-Europe unveils renewed vision as the must-attend global biopharma strategy forum

/in

2026 marks BIO-Europe’s evolution from partnering-led conference into the continent’s largest biopharma strategy forum Expands its program to convene the full C-suite of strategy leaders, building on its commitment to open dialogue and constructive partnerships Seven integrated tracks and high-impact plenary sessions to address the forces reshaping the global biopharma industry London, UK – 18 […]

Read more
© Optimum Strategic Communications.